SCHEMBL28022122

SCHEMBL28022122

Cc1cc(Nc2cc(N3CCN(C)CC3)nc(S(C)(=O)=O)n2)[nH]n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 17/20 0.46
AURKB Q96GD4 6/20 0.44
EGFR P00533 2/20 0.44
NTRK1 P04629 3/20 0.43
IGF1R P08069 1/20 0.43
PLK4 O00444 2/20 0.42
ABL1 P00519 2/20 0.42
LCK P06239 2/20 0.42
CSF1R P07333 2/20 0.42
RET P07949 2/20 0.42
KIT P10721 2/20 0.42
FGFR1 P11362 2/20 0.42
SRC P12931 2/20 0.42
PDGFRA P16234 2/20 0.42
TYK2 P29597 2/20 0.42
KDR P35968 2/20 0.42
FLT3 P36888 2/20 0.42
PTK2 Q05397 2/20 0.42
MAP4K5 Q9Y4K4 2/20 0.42
CHEK1 O14757 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2205962 0.88 AURKA (0.44) AURKAAURKBIGF1RJAK2JAK3
SCHEMBL28021594 0.84 HRH4 (0.48) AURKAAURKBNTRK1IGF1RPLK4
SCHEMBL28565380 0.81 HRH4 (0.51) AURKAAURKBEGFRNTRK1RET
SCHEMBL28022117 0.81 HRH4 (0.52) AURKAAURKBEGFRNTRK1KDR
SCHEMBL2201772 0.80 AURKA (0.52) AURKAAURKBEGFRNTRK1IGF1R
SCHEMBL28557378 0.79 HRH4 (0.48) AURKA
SCHEMBL2712009 0.78 AURKA (0.59) AURKAAURKBEGFRNTRK1IGF1R
SCHEMBL63682 0.77 AURKA (0.46) AURKAAURKBIGF1RPLK4ABL1
SCHEMBL2712007 0.77 AURKA (0.59) AURKAAURKBEGFRNTRK1IGF1R
SCHEMBL2713050 0.76 AURKA (0.57) AURKAAURKBEGFRNTRK1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112755193-A Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof 德玛医药 2021-05-07 CN disclosed
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 CN disclosed